Seelos Therapeutics, Inc. announced it will collaborate with the Sean M. Healey & AMG Center for ALS in an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS. Under this EAP, Seelos plans to initially enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS in parallel to its ongoing Phase II/III study on the HEALEY Platform.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 USD | -7.50% | -16.54% | -90.02% |
16/05 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
14/05 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
1st Jan change | Capi. | |
---|---|---|
-90.02% | 2.89M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.22% | 22.48B | |
-9.74% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- SEEL Stock
- News Seelos Therapeutics, Inc.
- Seelos Therapeutics, Inc. to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program